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Several epidemiological studies have reported positive associa-
tions between prostate cancer risk and adult height (Le Marchand
et al, 1994; Andersson et al, 1996, 1997; Giovannucci et al, 1997;
Hebert et al, 1997). However, the risk for clinically important
(advanced) prostate cancer has been examined separately by only
one previous study, in which a stronger positive association with
height was observed for advanced forms of this disease
(Giovannucci et al, 1997). The significance of the association with
height has not been determined, but it suggests the existence of
important growth-related risk factors for prostate cancer, possibly
involving endocrine mechanisms. For example, androgens and
insulin-like growth factor-1 (IGF-1) may influence the attainment
of height particularly during puberty (Keenan et al, 1993; Juul et
al, 1995), and circulating levels of these hormones in adults have
been positively associated with prostate cancer risk (Gann et al,
1996; Mantzoros et al, 1997; Chan et al, 1998). The underlying
determinants of height are largely genetic. Familial risk factors for
prostate cancer are also well-established with a two- to threefold
increase in risk in men with one or more affected first-degree rela-
tives (Giovannucci, 1995). The identification of susceptibility loci
on chromosome 1 (Smith et al, 1996) and the X-chromosome (Xu
et al, 1998) strongly supports the existence of inherited suscepti-
bility genes for prostate cancer but the mechanisms involved in
familial prostate cancer are unknown. In particular, a possible role
played by growth-related endocrine mechanisms in familial
prostate cancer has received little previous attention. The aims of
our study were twofold; first, to investigate associations between
adult height and the risk of localized compared with advanced
prostate cancer, and secondly; to examine height-related risks for
familial compared with sporadic prostate cancer.
MATERIALS AND METHODS
The Auckland Prostate Study is a population-based case–control
study carried out in the greater metropolitan area of Auckland,
New Zealand. The study population included all men aged 40–80
years normally resident in the Auckland area during the 13-month
study recruitment period from January 1996. Since almost all men
in this group with newly diagnosed prostate cancer attend urolo-
gists, urology clinics were used as the basis for case-attainment. In
this study, all public hospital urology clinic attendees and patients
attending five of seven private clinic urologists were eligible for
participation (an estimated 91% of all eligible patients). Wherever
possible, the study aimed to identify prostate cancer cases (aged
40–80 years) from a larger group of men who were recruited
prospectively following referral to the urology clinics for investi-
gation of prostate-related conditions. For these men, data collec-
tion preceded their knowledge of the prostate cancer diagnosis.
This was designed to reduce recall bias and improve response
rates. Histology reports were used as a back-up means of identi-
fying and recruiting remaining prostate cancers from urology
clinics retrospective to the date of diagnosis.
All cases were histologically confirmed, and patients with a
previous diagnosis of prostate cancer were excluded. Sub-groups
of men with ‘advanced’ and ‘localized’ prostate cancers were
defined prior to study analyses. Advanced cancers comprised
cases with either pathological or radiological (bone scintigraphy)
evidence of spread beyond the prostate capsule or a combined
Height-related risk factors for prostate cancer
AE Norrish1, CU McRae2, IM Holdaway3 and RT Jackson1
Department of 1Community Health, University of Auckland, Auckland, New Zealand; Departments of 2Urology and 3Endocrinology, Auckland Hospital, Auckland,
New Zealand.
Summary Previous studies have reported that adult height is positively associated with the risk of prostate cancer. The authors carried out
a population-based case–control study involving 317 prostate cancer cases and 480 controls to further investigate the possibility that height
is more strongly associated with advanced, compared with localized forms of this disease. Since the inherited endocrine factors, which in part
determine height attained during the growing years, may influence the risk of familial prostate cancer later in life, the relationship with height
was also investigated for familial versus sporadic prostate cancers. Adult height was not related to the risk of localized prostate cancer, but
there was a moderate positive association between increasing height and the risk of advanced cancer (relative risk (RR) = 1.62; 95%
confidence interval (CI) 0.97–2.73, upper versus lowest quartile, P-trend = 0.07). Height was more strongly associated with the risk of prostate
cancer in men with a positive family history compared with those reporting a negative family history. The RR of advanced prostate cancer for
men in the upper height quartile with a positive family history was 7.41 (95% CI 1.68–32.67, P-trend = 0.02) compared with a reference group
comprised of men in the shortest height quartile with a negative family history. Serum insulin-like growth factor-1 levels did not correlate with
height amongst men with familial or sporadic prostate cancers. These findings provide evidence for the existence of growth-related risk
factors for prostate cancer, particularly for advanced and familial forms of this disease. The possible existence of inherited mechanisms
affecting both somatic and tumour growth deserves further investigation. © 2000 Cancer Research Campaign
Keywords: prostate neoplasms; height; growth; familial; IGF-1
241
British Journal of Cancer (2000) 82(1), 241–245
© 2000 Cancer Research Campaign
Article no. bjoc.1999.0906
Received 9 March 1999
Revised 26 May 1999
Accepted 7 June 1999
Correspondence to: AE NorrishGleason score greater than or equal to seven. Localized cancers
included the mutually exclusive group with no evidence of extra-
capsular extension and a combined Gleason score of six or less.
Study controls comprised men aged 40–80 years, with no history
of prostate cancer, randomly selected from the Auckland general
electoral rolls. Control participants were group-matched to cases
on a monthly basis during the study recruitment period using 10-
year age groups and an approximate case:control ratio of 1:1.5.
Approval to carry out the study was obtained from the Northern
Regional Health Authority Ethics Committee and informed
written consent was obtained from all participants.
Study participants completed self-administered questionnaires
that collected personal, socio-demographic, anthropometric,
dietary and lifestyle data. Height (without shoes) and weight (with
light clothing) were self-reported. Participants were asked whether
first-degree relatives (parents or siblings) had been diagnosed with
cancer, and for each cancer, to specify the site and age at which it
had first developed. Identical procedures were used for exposure
data collection from cases and controls. Research nurses visited all
participants at home to obtain blood samples and to check the
completeness of responses to the questionnaires which had been
posted to participants previously. Participants with missing
responses were encouraged to fully complete the questionnaires
(self-administered) at the time of the visit. Although the nurse-
interviewers were not ‘blind’ to the case–control status of partici-
pants, neither they nor the participants were aware of specific
hypotheses concerning prostate cancer risk.
During the study recruitment period, 10 ml of whole blood were
collected in EDTA and transported promptly to the laboratory in
chilled polystyrene containers. Serum samples were stored in
cryovials (Greiner) at –82°C for an average period of 2 years prior
to further analysis in October 1998, to determine serum IGF-1
levels. Serum IGF-1 was measured by radioimmunoassay after
acid–ethanol cryoprecipitation, using a rabbit antiserum to recom-
binant human metIGF-1, and using metIGF-1 labelled with chlor-
amine-T. The assay sensitivity was 2 mg l–1 and the intra- and
inter-assay coefficients of variation were 5% and 7% respectively
(Gluckman et al, 1983). For the purposes of the current analyses,
serum IGF-1 was measured for cases reporting a positive family
history of prostate cancer (familial cases) and an age- and height-
matched group of cases selected randomly from those with a nega-
tive family history (sporadic cases). For these participants, age
was matched to within 1 year and height to within 5 cm. Prior to
blood analyses it was estimated that a comparison involving 31
pairs would possess 80% power to detect a 20 mg l–1 difference in
mean serum IGF-1 between familial and sporadic cancer groups
(assuming a variance of the differences of 40 mg l–1 and alpha =
0.05).
Relative risks for total, localized and advanced prostate cancers
were calculated for men in quartile categories for height, weight
and body-mass index [weight (kg)/height (m)2], with the reference
group comprised of those in the lowest quartile (quartile categories
were based upon distribution in the control group). The prostate
cancer risk for men who reported a positive family history of at
least one first-degree relative affected by prostate cancer was
compared with those reporting a negative history. Men whose
family histories of cancer were reported as ‘unknown’ were
excluded from these analyses. Age-adjusted relative risks were
calculated for prostate cancer, since controls were matched to
cases by age group during recruitment. Multivariate relative risks
were calculated using an unconditional logistic regression model.
Age was included as a continuous variable in regression models,
but other co-variates were included as categorical terms. A number
of socio-demographic, anthropometric and dietary co-variates
were considered as potential confounders of the association
between family history, height and prostate cancer. Socio-
economic status was defined by the participants’ usual current or
former occupation (if retired), according to the modified
Elley–Irving Classification (Johnston, 1983) which has been
widely used in New Zealand population research. A test for overall
trend across height categories used the P-values from a logistic
regression model which included ordinal terms for each quartile of
height, as well as confounding co-variates. The presence of an
interaction between family history and height (continuous vari-
able) was tested by including these two variables and a product
term, along with other potentially confounding co-variates, in a
logistic regression model.
RESULTS
Participants in the Auckland Prostate Study included a total of 480
controls (71% response rate) and 317 prostate cancer cases (77%
response rate), including 192 advanced cases and 125 localized
cases. The socio-economic status of the control group was
modestly elevated compared with cases, but due to the age-
matched recruitment process there was little difference in age
distribution.
There was a weak positive association between height and risk
of total prostate cancer risk which was not statistically significant
at the 95% level of confidence (Table 1). Although height was not
associated with the risk of localized prostate cancer, the risk of
advanced cancers, adjusted for age and socio-economic status, was
more strongly associated with increasing height (relative risk,
upper:lowest quartile = 1.62; 95% confidence interval (CI)
0.97–2.73,  P-trend = 0.07). Adjustment for socio-economic status
strengthened the positive associations with height since a weak
positive association existed between socio-economic status and
height in the study population. However, adjustment for a number
of dietary co-variates made little difference to the observed rela-
tive risk (RR) estimates. Weight and body-mass index were not
associated with prostate cancer risk (data not shown).
The RR for men with at least one first-degree relative reported
to be affected by prostate cancer (compared with no affected first-
degree relatives) was 2.84 (95% CI 1.46–5.50), based upon 26
cases and 15 controls with a positive family history. Table 2
presents height-related risks for prostate cancer, stratified by
family history status. The positive association with height was
stronger for men reporting a positive family history compared with
those with a negative family history, although these analyses
included relatively small numbers of men in the study with a posi-
tive family history. The multivariate relative risk of advanced
prostate cancer for men in the upper height quartile with a positive
family history was 7.41 (95% CI 1.68–32.67, P-trend = 0.02),
compared with a reference group comprised of men in the shortest
height quartile with a negative family history. A positive interac-
tion between family history and height was observed for advanced
prostate cancers (P = 0.04), but this was weaker for total cancers
(P = 0.14).
In order to investigate the hypothesis that the difference in
height-related risks observed between familial and sporadic
242 AE Norrish et al
British Journal of Cancer (2000) 82(1), 241–245 © 2000 Cancer Research Campaigncancers may be attributable to differences in circulating levels of
IGF-1, we compared serum levels of IGF-1 between groups. Mean
serum IGF-1 levels were lower for familial prostate cancer cases
compared with a random sample of age- and height-matched
sporadic prostate cancers. There was no clear correlation between
serum IGF-1 levels and increasing quartiles of height for either
group (Table 3).
DISCUSSION
This study confirms the findings of previous studies reporting
progressive increase in prostate cancer risk associated with
increasing adult height. Elevated height-related risks applied
mainly to advanced cancers, and were greater for men reporting a
positive family history of prostate cancer.
Incomplete response rates observed amongst cases (77%) and
controls (71%) in our study are typical for population-based
case–control studies and are unlikely to have resulted in selection
biases in relation to height. The exclusion of cases attending two
out of seven private urologists (an estimated 9% of the total
number of cases) may have contributed to the observed imbalance
in the socio-economic status of cases and controls but all analyses
were adjusted for this variable. Previous validation studies have
suggested that self-reported heights may be over-estimated by
shorter men when compared with measured height (Palta et al,
1982; Millar, 1986; Stewart et al, 1987). However, such misclassi-
fication would be expected to lead to underestimation of the posi-
tive association observed between height and prostate cancer risk.
The relatively small numbers of men in our study with familial
prostate cancer has resulted in limited precision of the estimates of
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Table 1 Relative risk of prostate cancer and self-reported height, by quartile, for total, localized and advanced cancer cases, Auckland Prostate Study,
1996–1997
Relative risk (95% CI), by height quartilea
Height quartile
Q1 Q2 Q3 Q4 P for trend
(< 170 cm) (170–173 cm) (173–179 cm) (>179 cm)
Total cancers Age-adjusted RR 1.00 1.31 (0.86–2.00) 1.31 (0.86–2.01) 1.24 (0.81–1.91) 0.39
Multivariate RRb 1.00 1.34 (0.88–2.05) 1.40 (0.91–2.16) 1.39 (0.90–2.14) 0.16
Number of cases:controlsc 58:110 88:129 85:120 82:121
Localized cancersd Age-adjusted RR 1.00 1.28 (0.73–2.27) 1.10 (0.62–1.87) 0.92 (0.51–1.68) 0.68
Multivariate RRb 1.00 1.11 (0.63–1.96) 1.09 (0.61–1.95) 1.00 (0.55–1.83) 0.99
Number of cases:controlsc 26:110 37:129 33:120 28:121
Advanced cancerse Age-adjusted RR 1.00 1.37 (0.82–2.28) 1.46 (0.88–2.44) 1.50 (0.90–2.50) 0.13
Multivariate RRb 1.00 1.38 (0.83–2.31) 1.55 (0.92–2.60) 1.62 (0.97–2.73) 0.07
Number of cases:controlsc 32:110 51:129 52:120 54:121
a Numbers of controls in quartile categories varied due to rounding of self-reported heights and selection of cut-off values to the nearest cm. bRelative risk
adjusted for age and socio-economic status in an unconditional logistic regression model. Reference group: men in lowest quartile. cTotal numbers may be
incomplete due to missing data for some observations. dLocalized cancers defined as combined Gleason score ≤ six and no evidence of extra-capsular spread.
eAdvanced cancers defined as combined Gleason score ³ seven or evidence of extra-capsular spread.
Table 2 Height, family history and prostate cancer relative risk, for total and advanced cancer cases, Auckland Prostate Study, 1996–1997
Relative risk (95% CI), by height quartilea
Height quartile
Q1 Q2 Q3 Q4 P for trend
(< 170 cm) (170–173 cm) (173–179 cm) (>179 cm)
Total cancers:
Negative family history Age-adjusted RR 1.00a 1.27 (0.81–1.99) 1.15 (0.72–1.82) 1.09 (0.69–1.74)
Multivariate RRb 1.00a 1.29 (0.82–2.03) 1.22 (0.76–1.94) 1.22 (0.76–1.96)
Number of cases:controlsc 49:96 75:118 67:112 65:112
Positive family historyd Age-adjusted RR 1.30 (0.28–6.14) 3.56 (0.99–12.76) 4.02 (1.17–13.79) 4.28 (1.05–17.36) 0.02
Multivariate RRb 1.27 (0.27–6.07) 3.54 (0.97–12.97) 4.78 (1.36–12.77) 5.49 (1.31–22.94) 0.004
Number of cases:controlsc 3:4 7:4 9:4 7:3
Advanced cancers:
Negative family history Age-adjusted RR 1.00a 1.27 (0.74–2.19) 1.18 (0.68–2.05) 1.15 (0.66–1.99)
Multivariate RRb 1.00a 1.28 (0.74–2.20) 1.25 (0.71–2.18) 1.25 (0.71–2.20)
Number of cases:controlsc 29:96 45:118 41:112 40:112
Positive family historyd Age-adjusted RR 0.78 (0.08–7.30) 2.62 (0.55–12.41) 2.17 (0.45–10.42)  6.25 (1.46–26.71) 0.06
Multivariate RRb 0.81 (0.09–7.58) 2.83 (0.58–13.73) 2.72 (0.55–13.47) 7.41 (1.68–32.67) 0.02
Number of cases:controlsc 1:4 3:4 3:4 6:3
a Reference group: men in the first quartile of height and no first degree relatives with prostate cancer. bRelative risk adjusted for age and socio-economic status
in an unconditional logistic regression model. cNumbers are incomplete due to missing values for height and unknown family history for some observations.
d³ one first degree relative affected.effect derived from the analyses stratified by reported family
history, and these findings will require confirmation by other
studies. However, the magnitude of the increase in cancer risk
observed for men in the highest quartile of height with a positive
family history was relatively large. Furthermore, the progressive
increase in risk across increasing height categories and the positive
interaction observed between height and family history for
advanced cancers strengthens the evidence for a true association.
The stronger association observed with advanced prostate
cancers in our study suggests that height may act as a marker for an
aetiological factor of relevance to clinically significant variants of
prostate cancer (for example more aggressive clones of malignant
cells) or possibly for a factor acting at a relatively late stage in the
progression of localized to advanced disease. Only one previous
observational study has examined risk in relation to prostate cancer
stage, with very similar findings to our own (Giovannucci et al,
1997). A Swedish study which reported a stronger association
between height and fatal compared with incident cases (Andersson
et al, 1997) is also consistent with our findings.
Additional evidence for the existence of growth-related consti-
tutional risk factors for prostate cancer is provided by the observa-
tion that prostate cancer risk is positively associated with
birthweight (Tibblin et al, 1995; Ekbom et al, 1996). Our analyses
further suggest that height-related risks may be greater for familial
forms of this disease. A possible explanation is that in high-risk
individuals, genetically-determined variability in circulating
hormones and growth factors may influence both height attained
during the growing years and familial prostate cancer risk later in
life. Prostate epithelial cells are rich in IGF-1 receptors and the
proliferative and apoptosis-inhibiting properties of IGF and
binding proteins in prostate cell lines (Cohen et al, 1991, 1994;
Rajah et al, 1997) suggest a potentially important role in cancer
processes. An increased risk of prostate cancer has been positively
associated with circulating IGF-1 levels in two previous studies
(Mantzoros et al, 1997; Chan et al, 1998). Growth-related
endocrine mechanisms for prostate carcinogenesis or cancer
progression involving IGF-1 therefore seem plausible. Androgen-
stimulated IGF-1 production has been shown to play a role in post-
pubertal somatic growth (Keenan et al, 1993; Juul et al, 1995),
although circulating IGF-1 has not been correlated with adult
height amongst older men (Goodman-Gruen and Barrett-Connor,
1997; Chan et al, 1998). Our preliminary analyses provided no
evidence to support the hypothesis that increased levels of circu-
lating IGF-1 may explain the increased risk observed amongst
taller men with familial prostate cancer, although the number of
study participants involved in this analysis was relatively small.
However, our observations did not allow the examination of
effects of circulating levels of IGF-1 prior to diagnosis, or of local
autocrine or paracrine production of IGF-1 in the prostate. Other
possible links between somatic growth and tumour development
might include local or systemic production of growth factors such
as IGF-II or fibroblast growth factor, IGF binding proteins or
growth factor receptors.
In summary, we have confirmed previous study findings indi-
cating a positive association between adult height and the risk of
prostate cancer, particularly advanced disease, and provide prelim-
inary evidence for a greater height-related risk for familial prostate
cancer. These findings suggest the existence of a factor or factors
capable of inducing somatic growth and promoting the develop-
ment of prostate carcinoma, a possibility deserving further study.
ACKNOWLEDGEMENTS
This work was supported by the Cancer Society of New Zealand
and the Health Research Council of New Zealand. The assistance
of the following urologists with the recruitment of participants is
acknowledged: Mr John Boulton, Mr Jon Cadwallader, Mr Roger
Chambers, Mr Russell McIlroy, Mr Derek Rothwell and Mr
Michael Rice. Special acknowledgement is made of technical
assistance given by Ms Cherie Mulholland, Ms Susan Hawkins
and Mrs Fleur O’Keefe and assistance with laboratory analyses
provided by Ms Francis Murray, Auckland Hospital Endo-
crinology Laboratory.
REFERENCES
Andersson S-O, Baron J, Bergstrom R, Lindgren C, Wolk A and Adami H-O (1996)
Lifestyle factors and prostate cancer risk: a case–control study in Sweden.
Cancer Epidemiol Biomarkers Prev 5: 509–513
Andersson S-O, Wolk A, Bergstrom R, Adami H-O, Engholm G, Englund A and
Nyren O (1997) Body size and prostate cancer: a 20-year follow-up study
among 135 006 Swedish construction workers. J Natl Cancer Inst 89: 385–389
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens
CH and Pollak M (1998) Plasma insulin-like growth factor-1 and prostate
cancer risk: a prospective study. Science 279: 563–566
Cohen P, Peehl DM, Lamson N and Rosenfield RG (1991) Insulin-like growth
factors (IGFs), IGF receptors and IGF binding proteins in primary cultures of
prostate epithelial cells. J Clin Endocrinol Metab 73: 401–407
Cohen P, Peehl DM, Graves HCB and Rosenfield RG (1994) Biological effects of
prostate specific antigen (PSA) as an IGF binding protein-3 (IGFBP-3)
protease. J Endocrinol 142: 407–415
Ekbom A, Hsieh CC, Lipworth L, Wolk A, Ponten J, Adami H-O and Trichopoulos
D (1996) Perinatal characteristics in relation to incidence of and mortality from
prostate cancer. Br Med J 313: 337–341
244 AE Norrish et al
British Journal of Cancer (2000) 82(1), 241–245 © 2000 Cancer Research Campaign
Table 3 Serum insulin-like growth factor-1 (IGF-1) in familial prostate cancer cases and an age- and height-matched sample of sporadic prostate cancers, by
quartile of height, Auckland Prostate Study, 1996–1997
Serum IGF-1 (mg/l) – mean ± standard deviation
Height quartile
Q1 Q2 Q3 Q4 All heights
(< 170 cm) (170 cm–173 cm) (173–179 cm) (>179 cm)
Familial cases 188 ± 68 152 ± 73 144 ± 49 160 ± 67 159 ± 61
(n = 26)
Sporadic cases 203 ± 114 189 ± 82 165 ± 67 173 ± 60 179 ± 72
(n = 26)Gann PH, Hennekens CH, Ma J, Longcope C and Stampfer MJA (1996) A
prospective study of sex hormone levels and risk of prostate cancer. J Natl
Cancer Inst 88: 1118–1126
Giovannucci E (1995) Epidemiological characteristics of prostate cancer. Cancer 75:
1766–1777
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA and Willet WC (1997) Height,
body weight and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 6:
557–563
Gluckman PD, Johnson-Barret TJ, Butler J, Edgar BW and Gunn TR (1983) Studies
of insulin-like growth factors-I and -II by specific radioligand assays in
umbilical cord blood. Clin Endocrinol 19: 405–413
Goodman-Gruen D and Barrett-Connor E (1997) Epidemiology of insulin-like
growth factor-1 in men and women. Am J Epidemiol 145: 970–976
Hebert PR, Ajani U, Cook NR, Lee I, Chan KS and Hennekens CH (1997) Adult
height and incidence of cancer in male physicians (United States). Cancer
Causes Control 8: 591–597
Johnston R (1983) A Revision of Socio-economic Indices for New Zealand. New
Zealand Council for Educational Research: Wellington
Juul A, Dalgaard P, Blum WF, Bang P, Hall K and Michaelson KF (1995) Serum
levels of insulin-like growth factor (IGF)-binding protein-1 (IGFBP-3) in
healthy infants, children, and adolescents: the relation to IGF-1, IGF-II,
IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin
Endocrinol Metab 80: 2534–2542
Keenam BS, Richards GE, Ponder SW, Dakkas JS, Nagamani M and Smith ER
(1993) Androgen-stimulated pubertal growth: the effects of testosterone and
dihydrotestosterone on growth hormone and insulin-like growth factor-1 in the
treatment of short stature and delayed puberty. J Clin Endocrinol Metab 76:
996–1001
Le Marchand L, Kolonel LN, Wilkins LR, Myers BC and Hirohata T (1994) Animal
fat consumption and prostate cancer: a prospective study in Hawaii.
Epidemiology 5: 276–282
Mantzoros CS, Tzonou A, Signorello LB, Tricopoulos D and Adami H-O (1997)
Insulin-like growth factor-1 in relation to prostate cancer and benign prostatic
hyperplasia. Br J Cancer 76: 1115–1118
Millar WJ (1986) Distribution of body weight and height: comparison of estimates
based upon self-reported and observed measures. J Epidemiol Comm Hlth 40:
319–323
Palta M, Prineas RJ, Berman R and Hannan P (1982) Comparison of self-reported
and measured height and weight. Am J Epidemiol 115: 223–230
Rajah R, Valentinis B and Cohen P (1997) Insulin-like growth factor (IGF)-binding
protein-3 induces apoptosis and mediates the effects of transforming growth
factor-beta 1 on programmed cell death through a p53- and IGF-independent
mechanism. J Biol Chem 272: 12181–12188
Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, et al (1996)
A genome-wide search reveals a major susceptibility locus for prostate cancer
on chromosome 1. Science 274: 1371–1373
Stewart AW, Jackson RT, Ford MA and Beaglehole R (1987) Underestimation of
relative weight by use of self-reported height and weight. Am J Epidemiol 125:
122–126
Tiblin G, Eriksoon S, Cnattingius S and Ekbom A (1995) High birthweight as a
predictor of prostate cancer risk. Epidemiology 6: 423–424
Xu J, Myers D, Freije D, Isaacs S, Wiley K, Nusskern D, et al (1998) Evidence for a
prostate cancer susceptibility locus on the X chromosome. Nat Genet 20:
175–179
Height-related risk factors for prostate cancer 245
British Journal of Cancer (2000) 82(1), 241–245 © 2000 Cancer Research Campaign